48298
3SBio Inc.
Dec 17, 2024
China
East Asia and the Pacific
Mar 18, 2024
B - Limited
Active
Oct 25, 2025
CM4S2 - Regional Industry - MAS Asia & Pac/MAS Services, EAP
other
Approved : Mar 18, 2024
Signed : May 10, 2024
Invested : Oct 21, 2025
other
Founded in 1993 and headquartered in Liaoning, 3SBio Inc. (“3SBio” or the “Company”) is a pioneer in the Chinese biotechnology industry that is primarily involved in the development of biopharmaceutical products to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology and other diseases or conditions.
The proposed investment will support 3SBio to fund: (i) the expansion of its research and manufacturing facilities in Liaoning Province, a frontier province in Northern China, and Guangdong Province; and (ii) Company’s expansion overseas in emerging market (the “Project”). The Project is expected to support the improved access to innovative, yet affordable, biopharmaceutical products in China and other developing nations.
For Inquiries About the Project, Contact
For Inquiries and Comments About IFC, Contact
Local Access of Project Documentation
Environmental documents will be made accessible to locally affected communities.